CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

被引：424

作者：

Choi, Bryan D. ^{[1
,2
,3
]}

Yu, Xiaoling ^{[1
,2
]}

Castano, Ana P. ^{[1
,2
]}

Bouffard, Amanda A. ^{[1
,2
]}

Schmidts, Andrea ^{[1
,2
]}

Larson, Rebecca C. ^{[1
,2
]}

Bailey, Stefanie R. ^{[1
,2
]}

Boroughs, Angela C. ^{[1
,2
]}

Frigault, Matthew J. ^{[1
,2
,4
]}

Leick, Mark B. ^{[1
,2
]}

Scarfo, Irene ^{[1
,2
]}

Cetrulo, Curtis L. ^{[2
,5
]}

Demehri, Shadmehr ^{[2
,6
]}

Nahed, Brian V. ^{[2
,3
]}

Cahill, Daniel P. ^{[2
,3
]}

Wakimoto, Hiroaki ^{[2
,3
]}

Curry, William T. ^{[2
,3
]}

Carter, Bob S. ^{[2
,3
]}

Maus, Marcela V. ^{[1
,2
,4
]}

机构：

[1] Massachusetts Gen Hosp, Canc Ctr, Cellular Immunotherapy Program, Boston, MA 02114 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA

[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA

[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA

[6] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA

来源：

NATURE BIOTECHNOLOGY | 2019年 / 37卷 / 09期

基金：

美国国家卫生研究院;

关键词：

GROWTH-FACTOR RECEPTOR; GLIOBLASTOMA; EGFR; DELIVERY; RECOGNITION; REGRESSION; DENSITY; VARIANT; MODELS;

D O I：

10.1038/s41587-019-0192-1

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to heterogeneous target antigen expression and outgrowth of tumors lacking the antigen targeted by CAR-T cells directed against single antigens. Here, we developed a bicistronic construct to drive expression of a CAR specific for EGFRvIII, a glioblastoma-specific tumor antigen, and a bispecific T-cell engager (BiTE) against EGFR, an antigen frequently overexpressed in glioblastoma but also expressed in normal tissues. CART. BiTE cells secreted EGFR-specific BiTEs that redirect CAR-T cells and recruit untransduced bystander T cells against wild-type EGFR. EGFRvIII-specific CAR-T cells were unable to completely treat tumors with heterogenous EGFRvIII expression, leading to outgrowth of EGFRvIII-negative, EGFR-positive glioblastoma. However, CART. BiTE cells eliminated heterogenous tumors in mouse models of glioblastoma. BiTE-EGFR was locally effective but was not detected systemically after intracranial delivery of CART. BiTE cells. Unlike EGFR-specific CAR-T cells, CART. BiTE cells did not result in toxicity against human skin grafts in vivo.

引用

页码：1049 / +

页数：12

共 38 条

[11] Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody [J].

Choi, Bryan D. ;

Gedeon, Patrick C. ;

Herndon, James E., II ;

Archer, Gary E. ;

Reap, Elizabeth A. ;

Sanchez-Perez, Luis ;

Mitchell, Duane A. ;

Bigner, Darell D. ;

Sampson, John H. .

CANCER IMMUNOLOGY RESEARCH, 2013, 1 (03) :163-167

[12] Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma [J].

Choi, Bryan D. ;

Suryadevara, Carter M. ;

Gedeon, Patrick C. ;

Herndon, James E., II ;

Sanchez-Perez, Luis ;

Bigner, Darell D. ;

Sampson, John H. .

JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (01) :189-190

[13] Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma [J].

Choi, Bryan D. ;

Kuan, Chien-Tsun ;

Cai, Mingqing ;

Archer, Gary E. ;

Mitchell, Duane A. ;

Gedeon, Patrick C. ;

Sanchez-Perez, Luis ;

Pastan, Ira ;

Bigner, Darell D. ;

Sampson, John H. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (01) :270-275

[14] Bispecific antibodies engage T cells for antitumor immunotherapy [J].

Choi, Bryan D. ;

Cai, Mingqing ;

Bigner, Darell D. ;

Mehta, Ankit I. ;

Kuan, Chien-Tsun ;

Sampson, John H. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) :843-853

[15] Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges [J].

Day, Chi-Ping ;

Merlino, Glenn ;

Van Dyke, Terry .

CELL, 2015, 163 (01) :39-53

[16] Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors [J].

Felsberg, Joerg ;

Hentschel, Bettina ;

Kaulich, Kerstin ;

Gramatzki, Dorothee ;

Zacher, Angela ;

Malzkorn, Bastian ;

Kamp, Marcel ;

Sabel, Michael ;

Simon, Matthias ;

Westphal, Manfred ;

Schackert, Gabriele ;

Tonn, Joerg C. ;

Pietsch, Torsten ;

von Deimling, Andreas ;

Loeffler, Markus ;

Reifenberger, Guido ;

Weller, Michael .

CLINICAL CANCER RESEARCH, 2017, 23 (22) :6846-6855

[17] EFFECTS OF TREATMENT ON LONG-TERM SURVIVORS WITH MALIGNANT ASTROCYTOMAS [J].

IMPERATO, JP ;

PALEOLOGOS, NA ;

VICK, NA .

ANNALS OF NEUROLOGY, 1990, 28 (06) :818-822

[18] Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma [J].

Johnson, Laura A. ;

Scholler, John ;

Ohkuri, Takayuki ;

Kosaka, Akemi ;

Patel, Prachi R. ;

McGettigan, Shannon E. ;

Nace, Arben K. ;

Dentchev, Tzvete ;

Thekkat, Pramod ;

Loew, Andreas ;

Boesteanu, Alina C. ;

Cogdill, Alexandria P. ;

Chen, Taylor ;

Fraietta, Joseph A. ;

Kloss, Christopher C. ;

Posey, Avery D., Jr. ;

Engels, Boris ;

Singh, Reshma ;

Ezell, Tucker ;

Idamakanti, Neeraja ;

Ramones, Melissa H. ;

Li, Na ;

Zhou, Li ;

Plesa, Gabriela ;

Seykora, John T. ;

Okada, Hideho ;

June, Carl H. ;

Brogdon, Jennifer L. ;

Maus, Marcela V. .

SCIENCE TRANSLATIONAL MEDICINE, 2015, 7 (275)

[19] Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection [J].

Kaech, Susan M. ;

Wherry, E. John .

IMMUNITY, 2007, 27 (03) :393-405

[20] Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells [J].

Kloss, Christopher C. ;

Condomines, Maud ;

Cartellieri, Marc ;

Bachmann, Michael ;

Sadelain, Michel .

NATURE BIOTECHNOLOGY, 2013, 31 (01) :71-+

← 1 2 3 4 →